|
|
News Breaks | | | | October 9, 2012 | | 05:55 EDT |  | NVLT, NVLT, ASTX, ASTX, ZIOP, ZIOP, BPAX, BPAX, TZYM, TZYM, ADXS, ADXS, DRTX, DRTX, GOVX, GOVX, RXII, RXII, THLD, THLD | Biotech Industry Organization to host a conference
11th Annual BIO Investor Forum is being held in San Francisco on October 9-10. | |
|
News For NVLT;RXII;GOVX;DRTX;ADXS;TZYM;BPAX;ZIOP;ASTX;THLD From The Last 14 Days Check below for free stories on NVLT;RXII;GOVX;DRTX;ADXS;TZYM;BPAX;ZIOP;ASTX;THLD the last two weeks. |
|
|
| June 18, 2013 | | 13:24 EDT | | BPAX | BioSante to host special shareholder meeting
 Subscribe for More Information | | | June 14, 2013 | | 06:02 EDT |  | ASTX | Astex Pharmaceuticals announced updated clinical results of SGI-110
Subscribe for More Information | | | June 11, 2013 | | 13:24 EDT | | TZYM | Risk Reward Capital reports 5.48% passive stake in Tranzyme
| | | 08:04 EDT | | ADXS | Advaxis requests orphan drug designation for ADXS-HPV
Advaxis announced that it has submitted an Application for Orphan Drug Designation with the U.S. Food and Drug Administration Office of Orphan Products Development for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus-associated head and neck cancer. "If granted, Orphan Drug Designation for our lead drug candidate, ADXS-HPV, could expedite our ability to help the over 10,000 Americans that the American Cancer Society estimates will be newly diagnosed with HPV-associated head and neck cancer in 2013. ODD would also provide seven years of market exclusivity for ADXS-HPV if it is approved by the FDA, tax credits on U.S. clinical trials, eligibility for orphan drug grants, and a waiver of the $1.9M regulatory application filing fee,” said CEO Thomas Moore. | | | June 6, 2013 | | 08:07 EDT | | ADXS | Advaxis withdraws proxy statement proposal to amend incentive plan
Subscribe for More Information | |
|
|
|
|
|
|
